Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2023-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Abion Inc.' (에이비온 주식회사) covering the period from 2023.01.01 to 2023.03.31. It contains detailed financial information, business operations, capital structure, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in holdings (including convertible bond conversions and acquisitions), and the purpose of investment (simple investment) by StarQuest Asset Management. This falls under the category of Major Shareholding Notification.
2023-05-08 Korean
[기재정정]주요사항보고서(유형자산양수결정)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding a 'Correction Report' (정정신고) for a 'Major Report' (주요사항보고서) concerning the acquisition of tangible assets (유형자산 양수 결정). It details specific changes to the acquisition date and payment schedule. Since this is a mandatory regulatory disclosure of a material corporate event that does not fit into specific categories like earnings, dividends, or management changes, it is classified as a general regulatory filing.
2023-04-25 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결) filed by the company Abion. It details the contract amount, duration, and terms. Since this is a specific regulatory disclosure of a material business event that does not fit into the other specialized categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2023-04-20 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of convertible bonds (CB) by Korea Investment Partners, resulting in a 5.72% stake in the company 'Abion'. This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) as it tracks changes in significant ownership levels.
2023-04-18 Korean
증권발행결과(자율공시)(제4회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the 'Result of Securities Issuance' (증권 발행결과) for a convertible bond (제4회차 전환사채). It details the issuance amount, payment date, and method. This falls under the category of capital and financing updates, specifically related to the issuance of debt instruments that can be converted into equity.
2023-04-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.